| 董丽红,白鹤,马艳荣.卡格列净联合胰岛素强化治疗T2DM患者胰岛素抵抗的变化.[J].中南医学科学杂志.,2023,(1):133-135. |
| 卡格列净联合胰岛素强化治疗T2DM患者胰岛素抵抗的变化 |
| Changes of insulin resistance in patients with T2DM after intensive treatment with kaglifloxacin combined with insulin |
| 投稿时间：2022-03-08 修订日期：2022-08-30 |
| DOI：10.15972/j.cnki.43-1509/r.2023.01.036 |
| 中文关键词: 2型糖尿病 卡格列净 胰岛素强化治疗 胰岛素抵抗 安全性 [ |
| 英文关键词:type 2 diabetes gliadine intensive insulin therapy insulin resistance security |
| 基金项目:新疆维吾尔自治区第五人民医院科研项目(YNKY-2021002) |
|
| 摘要点击次数: 164 |
| 全文下载次数: 119 |
| 中文摘要: |
| 目的探讨卡格列净联合胰岛素强化治疗2型糖尿病(T2DM)患者胰岛素抵抗的变化情况。 方法回顾性选择T2DM患者100例,按治疗方式分为联合组和胰岛素组。比较两组治疗期间空腹血糖(FBG)、餐后2h血糖(2hPG)、胰岛素用量、血糖达标时间、治疗前后胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β),以及不良反应发生情况。 结果与治疗前比较,治疗后两组FBG、2hPG均降低,且联合组降低更为显著(P＜0.05)。治疗后联合组日胰岛素用量低于胰岛素组；治疗后联合组HOMA-IR低于胰岛素组,HOMA-β高于胰岛素组(P＜0.05)。两组不良反应总发生率差异无显著性(P＞0.05)。 结论卡格列净联合胰岛素强化治疗T2DM,可改善患者胰岛素抵抗(IR),且安全性高,值得临床推广应用。 |
| 英文摘要: |
| AimTo explore the changes of insulin resistance in patients with type 2 diabetes (T2DM) treated by combination of carvedilol and insulin intensive therapy. Methods100 patients with T2DM were selected retrospectively, and divided into combined group and insulin group. Fasting blood glucose (FBG), postprandial blood glucose (2hPG), insulin dosage, blood glucose reaching the standard time, insulin resistance index (HOMA-IR), islet β cell function index (HOMA-β) before and after treatment, and the occurrence of adverse reactions were compared between the two groups. ResultsCompared with before treatment, FBG and 2hPG in both groups decreased after treatment, especially in the combined group (P＜0.05). After treatment, the daily insulin dosage of the combined group was lower than the insulin group. After treatment, HOMA-IR of the combined group was lower than the insulin group, and HOMA-β was higher than the insulin group (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). ConclusionCarglinide combined with intensive insulin therapy can improve the insulin resistance (IR) of patients with T2DM, and it is safe and worthy of clinical application. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|